



NASDAQ: EYES

Enriching the Lives of the Blind

May 2018

Forward Looking Statements




This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans," or "planned," "seeks," "may," "will," "expects," "intends," "believes," "should," and similar expressions, or the negative versions thereof, and which also may be identified by their context. All statements that address operating performance or events or developments that Second Sight expects or anticipates will occur in the future, such as stated objectives or goals, or that are not otherwise historical facts, are forward-looking statements. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report, on Form 10-K, filed on March 20, 2018, and our other reports filed from time to time with the Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto, or any change in events, conditions, or circumstances on which any such statement is based.



Two Breakthrough Technologies


Argus[®] II retinal prosthesis

- First and only FDA approved retinal prosthesis
- 20+ years and ~\$200 million invested to develop and commercialize
- Established technology with 276+ implants
- Approved for individuals with retinitis pigmentosa (bare-light and no-light perception in U.S.)



Orion[™] I visual cortical prosthesis system


- Leveraging Argus II technology
- Bypasses the retina and optic nerve to directly stimulate the brain
- Transformational technology with human trial initiated Q1 2018
- Broad label potential including:
 - Glaucoma, diabetic retinopathy, or forms of cancer and trauma





Argus[®] II: Effective Treatment for Blindness

Argus II is a retinal prosthesis that induces visual perception in individuals with severe to profound retinitis pigmentosa (RP)



Orion I: Breakthrough Device




Leveraging Argus II technology, our breakthrough Orion platform bypasses the damaged eye and/or optic nerve to directly stimulate the brain

- Orion has the potential to treat many forms of blindness including glaucoma, diabetic retinopathy, forms of cancer and trauma
- Received FDA Breakthrough Device designation
 - Completed initial FDA submission in 2018
 - Requested FDA meeting to discuss regulatory and clinical path forward
- Conducting a five subject feasibility study at **UCLA Medical Center** and the **Baylor College of Medicine** in Houston
 - First two human subjects implanted and activated*; phase 2 spatial mapping underway
 - Four of five subjects implanted with fifth planned for Q2 2018
 - No serious adverse events reported



Technology and commercial leadership positions us for growth



Commercial Experience and Leverage



Effective patient screening and rehabilitation workflows

High degree of patient qualification, best practices development, and pioneered post-surgical rehabilitation to improve patient satisfaction and outcomes



Scalable commercial infrastructure

Centers of Excellence, market access experience and leadership, channel with retinal surgeons—Infrastructure supports Orion commercialization



Market development

Established and growing new ophthalmology therapy in 14 markets worldwide, including the U.S., Canada, Europe, and Middle East




Argus II technology platform

Established technology with 10 years+ experience implant durability
Proprietary algorithms for artificial vision, leverage into Orion





Identifying and Recruiting Qualified Patients





2018 Key Drivers of Shareholder Value

Orion



Pivotal and post-market trial design via the FDA's Breakthrough Device Program. Addressable market opportunity evaluated by 3rd party



Complete Orion feasibility trial and release interim data, prepare for the initiation of the pivotal trial

Orion Path to Commercialization



Orion Feasibility Study



Argus II Next Gen Externals



Argus II Label Expansion



Argus II Commercial



Argus II



Submit regulatory filings for next-generation externals and execute commercial launch



U.S. label expansion to treat better vision RP patients



Extend and scale Centers of Excellence (COE) commercialization strategy (# of implant centers, U.S. patient database, implant volume in North America)



Select Financial Data

(USD \$ in thousands)	Q1 2018	FY 2017	FY 2016	Select projected financials at scale
<i>Implants</i>	16	75 <i>(30 in Q4)</i>	42 <i>(7 in Q4)</i>	Annual breakeven >400 Units
Revenue	\$976	\$7,964	\$3,985	
Gross Profit (Loss)	\$308	\$2,847	\$(6,091)	Gross margins +70%
Net Loss	\$(9,753)	\$(28,516)	\$(33,179)	
Non-GAAP Adjusted Net Loss ¹	\$(8,512)	\$(27,576)	\$(24,812)	

(USD \$ in thousands)	March 31, 2018	December 31, 2017
Cash and cash equivalents	\$5,014	\$7,839
Raised \$10 million in private placement in May 2018		
Debt	\$0	\$0



Second Sight Investment Highlights

- **Technology Innovator with two platforms**

- **Argus II retinal prosthesis**

- First and only FDA approved retinal prosthesis; 5+ year first mover advantage in the U.S.
 - 20 years and ~\$200 million invested in established technology

- **Orion I visual cortical prosthesis system**

- Leveraging Argus II technology to directly stimulate the brain
 - Human trial initiated Q1 2018

- **Large & Expanding Addressable Market**

- Argus II: Currently RP with bare-light or no-light perception in U.S.
 - Argus II Better Vision: 3-5x current addressable market
 - Orion I: Nearly all forms of blindness including glaucoma, diabetic retinopathy, or forms of cancer and trauma

- **Established Argus II Reimbursement**

- Currently the ONLY reimbursed retinal prosthesis treating blindness in U.S.
 - Reimbursement or funding in Canada, Germany, Italy, France and England

- **R&D Pipeline Expanding Market Potential**

- Next generation Argus II externals and advanced stimulation programs in development
 - Submitted HDE supplement to the FDA during 2018 to expand Argus II label
 - Four of five patients implanted with the Orion in 1H 2018



Second Sight Medical Products, Inc.

12744 San Fernando Road

Suite 400

Sylmar, CA 91342

Main: 818-833-5000

www.secondsight.com

Will McGuire

President & CEO

Direct: 818-833-5040

wmcguire@secondsight.com

Retail Investor Relations

Greg Falesnik

Managing Director

MZ North America

Direct: 949-385-6449

Greg.Falesnik@mzgroup.us

Institutional Investor Relations

Lisa Wilson

President

In-Site Communications, Inc.

Direct: 212-452-2793

lwilson@insitecony.com